Competitor Analysis: FGF-R Agonists and Antagonists
The present Competitive Intelligence Report about TGF-R agonists and antagonists provides a competitor evaluation in the field of transforming growth factor receptor (TGF-R) or TGF targeting molecules for tissue healing or treatment of cancer and fibrotic diseases of lung, skin or kidney as of November 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Transforming growth factor-beta (TGF-beta) family members are secreted multifunctional cytokines that play pivotal roles in development and disease. The prototypic member of this family, TGF-beta, plays a dual role in carcinogenesis, acting as a tumor suppressor in early stages and as tumor promoter in late stages of tumor progression. Aberrant TGF-beta expression is implicated in the pathogenesis of fibrosis in systemic sclerosis; thus, TGF-beta represents a molecular therapeutic target in this disease. Small-molecule inhibitors of TGF-beta-receptor activity are effective in animal models of fibrosis. TGF-beta1 is believed to play an important role in wound healing and repair, as it is a key regulator of the production and remodelling of the extracellular matrix through its effect on mesenchymal cells. Over the last few years, it has become evident that the signalling pathway of TGF-beta is complex with numerous receptor-ligand interactions, intracellular pathways and a number of mechanisms, which not only control the signalling but may also decide the response to the TGFbeta signal.
TGF and its receptor are targets for agonists and antagonists which are under development in a variety of diseases ranging from prevention of scarring and osteoarthritis to cancer (e.g., NSCLC; astrocytoma, melanoma, pancreatic cancer) and scleroderma, chronic kidney disease/glomerulosclerosis. Most of the molecules are biologics (antibodies, proteins, peptides, antisense, vaccine, cells). The most advanced projects are in phase III development.
The report includes a compilation of current active projects in research and development of molecules targeting TGF or the TGF receptor. In addition, the report lists company-specific R&D pipelines of TGF /-R targeting small molecules, antibodies, proteins, peptides, RNA, vaccine and cells. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
- TGF-R Agonists
- Biologics as TGF /-R Antagonists
- Small Molecule TGF Receptor Antagonists
- Corporate TGF-R Agonist and Antagonist R&D Pipelines
- About La Merie
The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations.
